LUMEVOQ gene therapy for LHON

Simon Ng — Wed, 13 Oct 2021 17:11:12 +0000

Magali Taiel, MD, GenSight Biologics SA, Paris, France, describes lenadogene nolparvovec (tradename LUMEVOQ®), a gene therapy being investigated for the treatment of Leber hereditary optic neuropathy (LHON), a rare, inherited form of vision loss. Lenadogene nolparvovec is a recombinant adeno-associated viral vector, serotype 2 (rAAV2/2) that specifically targets LHON-associated mutations in the ND4 mitochondrial gene. Data from two pivotal Phase III clinical trials, RESCUE (NCT02652767) and REVERSE (NCT02652780), demonstrated significant bilateral visual improvements in patients that received unilateral intravitreal injection of lenadogene nolparvovec. In addition, the Phase III REFLECT study (NCT03293524) demonstrated a significant benefit in visual acuity compared to baseline, with improved results seen in bilaterally injected patients. This interview took place at the Advanced Therapies Congress & Expo 2021.

RESCUE & REVERSE: long-term follow ups of LUMEVOQ gene therapy

admin_vjr_user — Tue, 08 Sep 2020 16:05:35 +0000

Magali Taiel, MD, of GenSight Biologics, Paris, France, discusses the long-term follow-up results of RESCUE and REVERSE, two Phase III clinical trials evaluating LUMEVOQ gene therapy in patients with Leber hereditary optic neuropathy. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

REVERSE – VJRegenMed

LUMEVOQ gene therapy for LHON

RESCUE & REVERSE: long-term follow ups of LUMEVOQ gene therapy